The Pharmaceutical Market: United Kindom

NEW YORK, March 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: United Kindom

http://www.reportlinker.com/p01117716/The-Pharmaceutical-Market-United-Kindom.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

Espicom market intelligence, brought to you by Business Monitor International

OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM

Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the disease in more than a decade. While this is positive news for both drugmakers, NICE's stamp of approval came only after the manufacturers of both drugs agreed to offer discounts, overturning a prior rejection of the treatments by the watchdog.

 

Headline Expenditure Projections:

Pharmaceuticals : GBP23.81bn (US$38.33bn) in 2011 to GBP23.74bn (US$37.27bn) in 2012; -0.3% in local currency terms and -2.8% in US dollar terms. Forecast unchanged from Q4 12.

Healthcare : GBP144.79bn (US$232.99bn) in 2011 to GBP149.35bn (US$234.48bn) in 2012; +3.2% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q4 12.

Medical devices : GBP5.89bn (US$9.48nn) in 2011 to GBP5.93bn (US$9.30bn) in 2012; +0.6% in local currency terms and -1.9% in US dollar terms. Forecast unchanged from Q4 12.

 

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

 

Table of Contents

SWOT Analysis 9

UK Pharmaceuticals And Healthcare Industry SWOT 9

UK Political SWOT 10

UK Economic SWOT 10

UK Business Environment SWOT 11

Pharmaceutical Business Environment Ratings 12

Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q113 12

Rewards 14

Risks 14

UK Market Summary 16

Regulatory Regime 17

Pharmaceutical Advertising 18

Intellectual Property Issues 19

Pricing Regime 20

Generic Drug Prices 23

Generic Substitution 24

OTC Prices 26

Reimbursement Regime 26

Patient Access Scheme 27

Table: Patient Access Schemes in Published Guidance, 2007-10 29

Patient Involvement in NHS 30

Industry Trends And Developments 31

Epidemiology 31

Non-Communicable Disease 31

Communicable Diseases 34

Healthcare Sector 34

Healthcare Reforms 35

Healthcare Funding 36

Healthcare IT 37

Health Insurance 38

Research & Development 40

Biotechnology 42

Clinical Trials 43

Medical Devices 45

Industry Forecast Scenario 46

Pharmaceutical Market Forecast 46

Table: Pharmaceutical Sales Indicators,2008-2016 47

Healthcare Market Forecast 48

Table: Healthcare Expenditure Indicators, 2008-2016 49

Table: Healthcare Governmental Indicators, 2008-2016 50

Table: Healthcare Private Indicators, 2008-2016 50

Key Growth Factors – Macroeconomic 51

Table: Macroeconomic Activity 54

Prescription Drug Market Forecast 55

Table: Prescriptions & Cost by Therapeutic Area in the UK, 2011 55

Table: Written Prescriptions, 2007-2011 (mn) 59

Table: Prescriptions by Value, 2007-11 (GBPmn) 59

Table: Prescription Drug Sales Indicators, 2008-2016 60

Patented Drug Market Forecast 61

Table: Patented Drug Market Indicators, 2008-2016 62

Generic Drug Market Forecast 63

Table: Prescriptions Written and Dispensed Generically in England by Value, 1996-11 (GBPmn) 63

Table: Generic Prescribing Rates by Therapeutic Area in England, 2006-11 (% by Volume) 64

Table: Generic Dispensing Rates by Therapeutic Area in England, 2006-11 (% by Volume) 64

Table: Generic Drug Sales Indicators, 2008-2016 66

OTC Medicine Market Forecast 67

Table: OTC Sales by Therapeutic Category at Retail Prices, 2008-11 (GBPmn) 68

Table: OTC Medicine Sales Indicators, 2008-2016 71

Table: Medicine Sales Breakdown, 2005-2010 71

Pharmaceutical Trade Forecast 72

Table: Exports and Imports Indicators, 2008-2016 74

Medical Device Market Forecast 75

Table: Medical Devices Sales Indicators 2008-2016 75

Other Healthcare Data 77

Key Risks To BMI Forecasts 78

Competitive Landscape 79

Pharmaceutical Industry 79

Table: Pharmaceutical Production, 1995-10 (Euros 000s) 79

Table: Top 20 UK-Based Pharmaceutical Companies According To Market Capitalisation 80

Table: Top 20 UK-Based Biotechnology Companies According To Market Capitalisation 81

Pharmaceutical Trade Associations 82

Table: Association of British Pharmaceutical Industry (ABPI) Full Members, 2011 82

Table: Members of the British Generic Manufacturers Association, 2012 84

Table: Full Members of the Proprietary Association of Great Britain (PAGB), 2011 84

Company Developments 85

Wholesale Sector 86

Table: Members of British Association of Pharmaceutical Wholesalers (BAPW), 2011 86

Retail Sector 88

Table: UK Registered Retail Pharmacies, 2010 91

Company Profiles 92

Leading Local Manufacturers 92

GlaxoSmithKline 92

AstraZeneca 97

Leading Multinational Manufacturers 103

Pfizer 103

Novartis 105

Sanofi 107

Merck & Co 109

Demographic Outlook 110

Table: The United Kingdom's Population By Age Group, 1990-2020 ('000) 111

Table: The United Kingdom's Population By Age Group, 1990-2020 (% of total) 111

Table: The United Kingdom's Key Population Ratios, 1990-2020 112

Table: The United Kingdom's Rural And Urban Population, 1990-2020 113

Glossary 114

BMI Methodology 116

How We Generate Our Pharmaceutical Industry Forecasts 116

Risk/Reward Ratings Methodology 117

Ratings Overview 117

Table: Pharmaceutical Business Environment Indicators 118

Weighting 119

Table: Weighting Of Components 119

To order this report:

Drug_and_Medication Industry: The Pharmaceutical Market: United Kindom

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.